Available Technologies
# of Displayed Technologies: 20 / 37
T-cells with Enhanced Ability to Respond to Exogenous Ligands
TS-066052 — Novel T-cells expressing the IL-2a receptor to enhance cancer cell targeting.
The Need
As interest in cell-based therapies, particularly for cancer treatment, continues to rise, there’s a critical need for therapeutic cells capable of robust proliferation in vivo. Existing methods relying on exogenous cytokines like IL-2 face challenges due to dose-limiting toxicity an…
- College: OSU Wexner Medical Center
- Inventors: Rubinstein, Mark
- Licensing Officer: Schultz, Teri
Novel Antibodies Targeting IL-2
TS-066051 — Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg.
IL-2 and its receptor IL-2R are known to play multiple roles in shaping the immune response, including both immune activation and tolerance. Expression of intermediate-affinity IL-2 receptors by different immune cell subsets determines cellular sensitivity to IL-2. However, the dynamic interplay bet…
- College:
- Inventors:
- Licensing Officer: Schultz, Teri
Gene Therapy Approach for Treating Neuropathy
TS-065913 — Gene therapy strategies for treating peripheral neuropathy.
Peripheral neuropathy (PN) results in loss of innervation by the peripheral nerves in tissues such as skin, muscle, heart, and adipose tissue. It is a painful, debilitating disease, that is estimated to affect between 20 and 30 million Americans. The number of Americans affected by PN is likely muc…
- College: College of Medicine (COM)
- Inventors: Townsend, Kristy; Blaszkiewicz, Magdalena; Cao, Lei
- Licensing Officer: Schultz, Teri
Targeting Telomerase to Treat Ocular Neovascular Disorders
TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.
Choroidal neovascularization (CNV) is the principal driver of blindness in neovascular age-related macular degeneration (nvAMD). Abnormal blood vessel growth beneath the macular leads to retinal damage and severe vision loss. Discovering the involvement of VEGF in the underlying mechanisms driving …
- College: College of Medicine (COM)
- Inventors: Kerur, Nagaraj
- Licensing Officer: Schultz, Teri
Treating Diabetes, Obesity, and Cardiovascular Disease by Reprogramming Skin
TS-065789 — Using tissue nano-transfection to reprogram skin cells to treat diabetes, obesity and/or cardiovascular health
The incidence of obesity and diabetes is skyrocketing, leading to chronic inflammatory conditions such as cardiovascular disease, autoimmune diseases, liver diseases, and cancer. Cardiovascular disease (CVD) is the leading cause of death across the US and worldwide and affects almost half of all ad…
- College: College of Medicine (COM)
- Inventors: Gallego Perez, Daniel; Higuita Castro, Natalia; Sen, Chandan
- Licensing Officer: Schultz, Teri
Revolutionizing Cancer Immunotherapy with Novel Chimeric B-cell Epitope Peptide Vaccines
TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.
The emergence of immune checkpoint inhibitors revolutionized cancer immunotherapy. Monoclonal antibodies targeting PD-1, PD-L1 and CTLA-4 have shown impressive clinical outcomes.
The Need
Despite their effectiveness, current monoclonal antibody treatments have limitations such as low response ra…
- College: College of Medicine (COM)
- Inventors: Kaumaya, Pravin
- Licensing Officer: Schultz, Teri
MicroRNA profile predicts colon cancer prognosis
TS-065453 — The Need:
Colon cancer remains one of the most prevalent and lethal forms of cancer worldwide. Timely and accurate diagnosis is critical for effective treatment and improved patient outcomes. Current diagnostic methods often lack the precision and sensitivity needed for early detection and prognosi…
- College: College of Medicine (COM)
- Inventors: Croce, Carlo
- Licensing Officer: Schultz, Teri
Enhancing Antibody Therapies Using a NOD2 Agonist
TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness of monoclonal antibody therapy.
An estimated 20,160 new cases of chronic lymphocytic leukemia (CLL) and 4,410 deaths were expected in 2022. Current therapies for CLL include the administration of a monoclonal antibody, such as rituximab, an anti-CD20 antibody, to promote clearance of malignant B cells.
The Need
Current therapies…
- College: College of Medicine (COM)
- Inventors: Tridandapani, Susheela; Butchar, Jonathan; Mehta, Payal; Merchand Reyes, Giovanna; Santhanam, Ramasamy
- Licensing Officer: Schultz, Teri
Novel Extracellular Vesicles Loaded with Anti-Inflammatory Agents
TS-065154 — , 2018-345 Revolutionary treatment for ARDS using novel extracellular vesicles loaded with Anti-Inflammatory Agents.
The Need
Acute Respiratory Distress Syndrome (ARDS) remains a significant healthcare challenge with high mortality rates and long-term morbidity. Despite advancements in supportive care, there’s an urgent need for pharmacologic treatments targeting the molecular mechanisms driving ARDS pathog…
- College: College of Medicine (COM)
- Inventors: Karpurapu, Manjula; Christman, John; Parinandi, Narasimham
- Licensing Officer: Schultz, Teri
Decision Support Tool for Prevention of Failure to Rescue Events
TS-064718 — A clinical decision support tool for minimizing failure to rescue events at hospitals.
Failure to rescue (FTR) is a serious issue in patient safety and healthcare quality for hospitalized patients. The term implies that rescue is possible, and death is, therefore, a failure. On any given day across the country, two-thirds of deaths in hospitals could be judged as preventable. In 2005,…
- College: OSU Wexner Medical Center
- Inventors: Garvey, Paula; Justice, Stephanie
- Licensing Officer: Schultz, Teri
Innovative Solutions for Acute Myeloid Leukemia: The Role of EGFL7
TS-064071 — EGFL7-centric technology for diagnosis, prognosis, and therapeutic strategies for hematologic malignancies.
The complex genetic landscape of Acute Myeloid Leukemia (AML), marked by chromosomal alterations and gene mutations, necessitates innovative approaches.
The Need
AML poses a significant challenge in the realm of hematologic malignancies, demanding both prognostic markers and novel treatments. Curr…
- College: College of Medicine (COM)
- Inventors: Dorrance, Adrienne; Garzon, Ramiro; Shen, Changxian
- Licensing Officer: Schultz, Teri
Skin Healing Technology: Dermal Substitutes and Engineered Skin with Rete Ridges
TS-064046 — Dermal substitute with engineered rete ridges improves epidermal-dermal communication and enhances burn wound treatment.
Massive burn injuries present a critical challenge in wound healing and prevention of infection. Current treatment methods are susceptible to blistering and other problems that can reduce engraftment.
The Need
Cultured epithelial autografts (CEAs) are a vital component in treating large burns, but…
- College: College of Engineering (COE)
- Inventors: Powell, Heather; Bailey, John; Blackstone, Britani "Niki"
- Licensing Officer: Schultz, Teri
Novel STK1-targeted small molecule "antibiotic resistance breaker" compounds
TS-063547 — Novel small molecule STK1 inhibitors that “break” the resistance of bacteria strains to antibiotics.
In today’s healthcare landscape, increasingly highly pathogenic and multidrug-resistant S. aureus (MDRSA) strains are replacing traditional methicillin-resistant S. aureus (MRSA) in both community and hospital settings.
The Need
The rise of these resilient multi-drug resistant bacteria has …
- College: College of Medicine (COM)
- Inventors: Pancholi, Vijay
- Licensing Officer: Schultz, Teri
Protecting the vascular endothelial barrier – a novel approach to treating atrial fibrillation
TS-063433 — A new pharmacologic modality for treating AFib.
Atrial fibrillation (AF) is the most common form of irregular cardiac rhythm (arrhythmia), affecting approximately 3% of the US population. It is a significant risk factor for heart failure, ischemic stroke, and sudden cardiac death. The AF mortality rate is growing globally, and risk factors known …
- College: College of Engineering (COE)
- Inventors: Veeraraghavan, Rengasayee; Mezache, Louisa
- Licensing Officer: Schultz, Teri
Gene Therapy Compositions for Treating Cardiovascular Diseases
TS-063091 — A gene therapy approach to address the specific needs of failing hearts.
Heart failure affects over 6 million adults in the US and can lead to irreversible damage to the heart.
The Need
In the realm of cardiovascular health and the management of heart-related disorders, there exists a pressing commercial need for a technology that can effectively address the challenge…
- College: College of Medicine (COM)
- Inventors: Lewandowski, E. Douglas; Carley, Andrew
- Licensing Officer: Schultz, Teri
Transforming PAH Management with PHORA: Empowering Physicians for Better Patient Care
TS-062764 — The Pulmonary Hypertension Outcomes Risk Assessment (PHORA): a PAH risk stratification tool.
Pulmonary Arterial Hypertension (PAH) demands precise risk stratification for effective patient management. Clinical decision support tools can help inform treatment decisions made by physicians and other healthcare providers, usually at the point of care.
The Need
Current methods for assistin…
- College: College of Medicine (COM)
- Inventors: Benza, Ray; Lin, Shili; Mathur, Puneet
- Licensing Officer: Schultz, Teri
Unlocking New Frontiers in Diabetic Retinopathy Detection: Introducing Vessel Orientation-Based Quantitative OCTA Technology
TS-062762 — Pinpointing previously concealed sectoral differences in the diabetic retina to diagnose DR earlier.
Diabetic Retinopathy (DR) is a leading cause of blindness globally, requiring early and accurate diagnosis for effective intervention.
The Need
Current diagnostic methods for DR lack the precision needed to identify subtle retinal microvascular changes in the disease’s early stages. There i…
- College: College of Medicine (COM)
- Inventors: Ma, Yanhui
- Licensing Officer: Schultz, Teri
A Breakthrough in Central Nervous System Repair
TS-062739 — Method to program pericytes for axon regeneration and spinal cord injury repair.
In the realm of central nervous system (CNS) repair, a critical need arises for innovative treatments that not only address the physical aspects of injury but also tackle the associated phychopathology. Understanding the cellular processes that occur after spinal cord injury (SCI) that are detrimen…
- College: College of Medicine (COM)
- Inventors: Tedeschi, Andrea
- Licensing Officer: Schultz, Teri
Revolutionizing Vascular Access Management for Hemodialysis Patients
TS-062693 — Dynamic AVF flow control: A paradigm shift in vascular access management for hemodialysis patients.
Patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD) face critical challenges in maintaining functional vascular access. Despite the superiority of arteriovenous fistulas (AVFs) in terms of longevity, infection rates, and cost-effectiveness, over a third of AVFs fail to mature a…
- College: College of Medicine (COM)
- Inventors: Boobes, Khaled
- Licensing Officer: Schultz, Teri
Addressing the Challenges in HCC Treatment with Innovative Technology
TS-062690 — Novel niclosamide analogues with improved bioavailability and mitigated dose-limiting toxicities.
Hepatocellular carcinoma (HCC) poses a significant global health challenge, being a predominant form of liver cancer with high mortality rates. The disease exhibits sexual dimorphism, disproportionately affecting males.
The Need
Despite the crucial role of androgen receptors (AR) in HCC progress…
- College: College of Pharmacy
- Inventors: Coss, Christopher; Cheng, Jeffrey; Cheng, Xiaolin; Kulp, Samuel; Li, Tom; Montgomery, Emma; Xing, Enming
- Licensing Officer: Schultz, Teri
